Alembic Limited
NSE: ALEMBICLTD BSE: ALEMBICLTD
NSE
112.07
1.00 (0.90%)
Prev Close
111.07
Open Price
111.5
Volume
591,652
Today Low / High
111.17 / 113.85
52 WK Low / High
85.46 / 169
Range
106 - 118
BSE
112.15
1.00 (0.90%)
Prev Close
111.15
Open Price
110.45
Volume
49,797
Today Low / High
110.45 / 113.8
52 WK Low / High
85.55 / 169
Range
107 - 118
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 112.07 (target range: 106 - 118), reflecting a change of 1 (0.90033%). On the BSE, it is listed at 112.15 (target range: 107 - 118), showing a change of 1 (0.89969%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
06 Jun
111.50
0.51%
05 Jun
111.00
0.06%
04 Jun
110.65
0.01%
03 Jun
113.79
-3.25%
02 Jun
110.43
2.69%
30 May
112.00
-1.31%
29 May
112.00
-0.23%
28 May
112.20
-0.37%
27 May
112.00
-0.10%
26 May
111.65
0.30%
23 May
110.05
1.12%
22 May
110.50
-0.48%
21 May
111.46
-0.75%
20 May
114.00
-2.81%
19 May
107.34
5.28%
16 May
106.58
0.45%
15 May
107.00
-0.39%
14 May
107.50
-0.19%
13 May
104.00
0.23%
12 May
99.80
4.39%
Alembic Limited Graph
Alembic Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Alembic Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 112.07, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 112.15 | 113.27 | 101.94 - 124.60 |
| 114.39 | 91.51 - 137.27 | ||
| 115.51 | 80.86 - 150.17 | ||
| Bearish Scenario | 112.15 | 111.03 | 99.93 - 122.13 |
| 109.91 | 87.93 - 131.89 | ||
| 108.79 | 76.15 - 141.42 |
Overview of Alembic Limited
ISIN
INE426A01027
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
652,952
Market Cap
28,777,558,628
Last Dividend
2.4
Official Website
IPO Date
2002-07-01
DCF Diff
187.26
DCF
-77
Financial Ratios Every Investor Needs
Stock Dividend of ALEMBICLTD
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-08-05 | August 05, 25 | 2.4 | 2.4 | 2025-08-05 | 2025-09-11 | |
| 2024-08-05 | August 05, 24 | 2.4 | 2.4 | 2024-08-05 | 2024-09-11 | |
| 2023-08-03 | August 03, 23 | 2.2 | 2.2 | 2023-08-03 | 2023-09-09 | |
| 2022-09-12 | September 12, 22 | 1.8 | 1.8 | 2022-09-13 | 2022-09-23 | |
| 2021-07-29 | July 29, 21 | 0.2 | 0.2 | 2021-07-30 | 2021-08-10 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 147.12 Cr | 59.88 Cr | 87.25 Cr | 0.5930 | 0.10 Cr | 6.70 Cr | 49.02 Cr | 268.62 Cr | 10.46 | 105.50 Cr | 1.8258 |
| 2023-03-31 | 118.34 Cr | 48.13 Cr | 70.21 Cr | 0.5933 | 0.66 Cr | 5.51 Cr | 33.61 Cr | 190.65 Cr | 7.42 | 93.99 Cr | 1.6110 |
| 2022-03-31 | 71.37 Cr | 30.92 Cr | 40.45 Cr | 0.5668 | 1.03 Cr | 6.36 Cr | 9.07 Cr | 222.06 Cr | 8.65 | 103.11 Cr | 3.1114 |
| 2021-03-31 | 67.84 Cr | 28.56 Cr | 39.27 Cr | 0.5789 | 0.39 Cr | 3.64 Cr | 9.65 Cr | 342.84 Cr | 13.35 | 21.34 Cr | 5.0539 |
| 2020-03-31 | 67.26 Cr | 37.69 Cr | 29.56 Cr | 0.4396 | 0.15 Cr | 4.83 Cr | 0.19 Cr | 329.12 Cr | 12.82 | 96.39 Cr | 4.8936 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 1.26 Cr | 2,328.77 Cr | 143.21 Cr | 2,185.5645 Cr | 9.15 Cr | 7.89 Cr | 92.60 Cr | 131.64 Cr | 0.00 Cr | 0.00 Cr | 1,774.71 Cr | 90.3159 Cr |
| 2023-03-31 | 0.93 Cr | 2,204.58 Cr | 126.55 Cr | 2,078.0328 Cr | 0.00 Cr | -0.93 Cr | 88.61 Cr | 131.96 Cr | 0.00 Cr | 1.81 Cr | 1,662.72 Cr | 83.8105 Cr |
| 2022-03-31 | 1.17 Cr | 2,631.95 Cr | 135.37 Cr | 2,496.5833 Cr | 0.00 Cr | -1.17 Cr | 86.87 Cr | 133.69 Cr | 0.00 Cr | 2.02 Cr | 2,349.90 Cr | 67.7648 Cr |
| 2021-03-31 | 5.89 Cr | 2,408.96 Cr | 111.93 Cr | 2,297.0281 Cr | 0.28 Cr | -5.61 Cr | 54.28 Cr | 139.53 Cr | 0.00 Cr | 1.94 Cr | 2,166.44 Cr | 59.4153 Cr |
| 2020-03-31 | 58.30 Cr | 1,470.72 Cr | 52.68 Cr | 1,418.0418 Cr | 0.03 Cr | -58.27 Cr | 35.41 Cr | 133.71 Cr | 0.00 Cr | 1.92 Cr | 1,025.15 Cr | 45.7974 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 22.6865 Cr | 25.8363 Cr | -48.1936 Cr | -33.6034 Cr | 0.3291 Cr | 1.2609 Cr | -56.2899 Cr | 102.6862 Cr | 9.1490 Cr | -56.2340 Cr | -3.9900 Cr |
| 2023-03-31 | 38.8525 Cr | 7.2960 Cr | -46.3882 Cr | 13.0346 Cr | -0.2396 Cr | 0.9318 Cr | -25.8179 Cr | 86.8000 Cr | 0.0000 Cr | -45.9228 Cr | -1.7400 Cr |
| 2022-03-31 | -17.7469 Cr | 18.8478 Cr | -5.8165 Cr | -53.5601 Cr | -4.7157 Cr | 1.1714 Cr | -35.8132 Cr | 97.8574 Cr | -0.2766 Cr | -5.1508 Cr | -32.5884 Cr |
| 2021-03-31 | -2.1817 Cr | -34.8694 Cr | -15.3620 Cr | -49.6370 Cr | -52.9679 Cr | 5.8871 Cr | -47.4553 Cr | 17.0412 Cr | 0.2766 Cr | -15.2767 Cr | -18.8683 Cr |
| 2020-03-31 | 6.5364 Cr | 56.7225 Cr | -6.4091 Cr | -15.8178 Cr | 56.8497 Cr | 58.8550 Cr | -22.3542 Cr | 93.1652 Cr | 0.0000 Cr | -6.1211 Cr | -0.0857 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 57.92 Cr | 17.00 Cr | 40.92 Cr | 0.7065 | 23.70 Cr | 65.39 Cr | 2.55 | 30.76 Cr | 1.1290 |
| 2024-09-30 | 52.91 Cr | 18.71 Cr | 34.20 Cr | 0.6464 | 16.90 Cr | 121.02 Cr | 4.71 | 85.18 Cr | 2.2873 |
| 2024-06-30 | 50.78 Cr | 16.08 Cr | 34.70 Cr | 0.6833 | 26.97 Cr | 55.82 Cr | 2.17 | 22.36 Cr | 1.0993 |
| 2024-03-31 | 49.04 Cr | 18.98 Cr | 30.06 Cr | 0.6130 | 22.67 Cr | 72.15 Cr | 2.81 | 26.19 Cr | 1.4712 |
| 2023-12-31 | 39.32 Cr | 14.13 Cr | 25.19 Cr | 0.6406 | 9.01 Cr | 61.42 Cr | 2.39 | 13.90 Cr | 1.5621 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 1.75 Cr | 44.01 Cr | 45.76 Cr | 43.46 Cr | 97.05 Cr | 199.72 Cr | 131.37 Cr | 2,440.96 Cr | 194.53 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 12.86 Cr | 0.00 Cr | 0.00 Cr | 12.86 Cr | 0.00 Cr | 0.00 Cr | -2,185.56 Cr |
| 2024-03-31 | 1.26 Cr | 11.64 Cr | 12.91 Cr | 21.90 Cr | 92.60 Cr | 137.39 Cr | 131.64 Cr | 2,328.77 Cr | 143.21 Cr |
| 2023-12-31 | -4.63 Cr | 9.26 Cr | 4.63 Cr | 0.00 Cr | 0.00 Cr | 4.63 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 1.88 Cr | 13.55 Cr | 15.43 Cr | 21.52 Cr | 86.54 Cr | 139.62 Cr | 131.71 Cr | 2,269.72 Cr | 150.06 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | 55.82 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 72.15 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 61.42 Cr | 5.32 Cr | 0.00 Cr | 0.00 Cr | 5.32 Cr | 8.49 Cr | 3.17 Cr | 0.00 Cr | 5.32 Cr |
| 2023-09-30 | 90.68 Cr | 3.72 Cr | 0.00 Cr | 0.00 Cr | 3.72 Cr | 3.17 Cr | 0.00 Cr | 0.00 Cr | 3.72 Cr |
| 2023-06-30 | 44.38 Cr | 3.66 Cr | 0.00 Cr | 0.00 Cr | 3.66 Cr | 5.54 Cr | 1.88 Cr | 0.00 Cr | 3.66 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2013-09-27 | September 27, 13 | 2:1 |
| 2006-09-26 | September 26, 06 | 5:1 |
| 2004-03-25 | March 25, 04 | 2:1 |
| 2003-12-10 | December 10, 03 | 1083:1000 |
| 1999-07-26 | July 26, 99 | 10:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,679.20 | ₹4,028,870,976,000.00 | ₹2,500,031.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,544.50 | ₹1,737,361,870,500.00 | ₹361,018.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,320.90 | ₹1,100,458,988,118.00 | ₹2,158,463.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,154.30 | ₹1,067,557,063,500.00 | ₹86,576.00 |
| Mankind Pharma Limited | MANKIND | ₹2,352.40 | ₹970,767,378,020.00 | ₹353,197.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹960.15 | ₹966,131,734,500.00 | ₹810,089.00 |
| Lupin Limited | LUPIN | ₹1,999.60 | ₹913,207,322,000.00 | ₹1,289,535.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,161.10 | ₹674,369,202,200.00 | ₹392,642.00 |
| Alkem Laboratories Limited | ALKEM | ₹4,862.50 | ₹581,384,812,500.00 | ₹181,782.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,590.20 | ₹448,756,030,200.00 | ₹940,265.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Cohance Lifesciences Limited | COHANCE | ₹1,055.10 | ₹403,646,450,141.00 | ₹209,681.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,370.90 | ₹347,802,813,600.00 | ₹594,702.00 |
| Laurus Labs Limited | LAURUSLABS | ₹642.05 | ₹346,227,388,650.00 | ₹1,658,718.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,571.30 | ₹321,186,225,600.00 | ₹84,218.00 |
| Piramal Enterprises Limited | PEL | ₹1,173.70 | ₹266,051,968,600.00 | ₹1,087,297.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,702.30 | ₹265,322,180,300.00 | ₹62,791.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,790.00 | ₹244,750,000,000.00 | ₹123,199.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,505.40 | ₹244,595,886,600.00 | ₹803,276.00 |
| Eris Lifesciences Limited | ERIS | ₹1,638.30 | ₹223,111,885,500.00 | ₹55,563.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹987.60 | ₹194,125,618,800.00 | ₹40,498.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,140.00 | ₹181,580,340,000.00 | ₹116,733.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,030.00 | ₹167,173,597,000.00 | ₹539,376.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,093.30 | ₹159,115,291,610.00 | ₹64,315.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹858.30 | ₹153,730,113,000.00 | ₹354,578.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹529.95 | ₹128,536,192,800.00 | ₹485,798.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,560.50 | ₹92,300,963,700.00 | ₹8,096.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹914.45 | ₹89,424,888,505.00 | ₹310,698.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹909.25 | ₹82,409,528,235.00 | ₹242,116.00 |
| Strides Pharma Science Limited | STAR | ₹782.30 | ₹72,098,880,210.00 | ₹430,298.00 |
| FDC Limited | FDC | ₹429.20 | ₹69,878,052,000.00 | ₹308,089.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹165.55 | ₹53,724,617,100.00 | ₹2,347,837.00 |
| Innova Captab Limited | INNOVACAP | ₹889.10 | ₹50,878,685,263.00 | ₹72,505.00 |
| Suven Life Sciences Limited | SUVEN | ₹221.19 | ₹48,235,788,060.00 | ₹1,475,325.00 |
| Sequent Scientific Limited | SEQUENT | ₹187.85 | ₹47,019,230,700.00 | ₹442,806.00 |
| Hikal Limited | HIKAL | ₹372.35 | ₹45,911,127,350.00 | ₹154,610.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹462.15 | ₹42,180,430,500.00 | ₹112,178.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹592.90 | ₹41,743,598,820.00 | ₹18,878.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹368.10 | ₹36,912,331,800.00 | ₹50,918.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹718.15 | ₹36,423,921,665.00 | ₹149,821.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,141.70 | ₹35,421,576,300.00 | ₹12,390.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹64.12 | ₹35,134,810,480.00 | ₹2,840,731.00 |
| Alembic Limited | ALEMBICLTD | ₹112.07 | ₹28,777,558,628.00 | ₹591,652.00 |
| IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹88.74 | ₹26,047,585,980.00 | ₹1,118,303.00 |
| Indoco Remedies Limited | INDOCO | ₹275.10 | ₹25,377,397,290.00 | ₹25,198.00 |
Key Executives
Company Secretary & Compliance Officer
Mr. Kevalkumar Bharatkumar Thakkar
Gender: male
Year Born:
MD, Chief Executive Officer & Executive Director
Ms. Malika Chirayu Amin
Gender: female
Year Born: 1955
President of Real Estate Operations
Mr. Avaneesh Nath Sharma
Gender: male
Year Born:
Chief Financial Officer
Mr. Rasesh Shah
Gender: male
Year Born:
Associate Vice President of HR
Mr. Ambarish Jambhorkar
Gender: male
Year Born:
FAQs about Alembic Limited
Who is the CEO of the company?
The CEO is Ms. Malika Chirayu Amin.
What is the current market price of the stock?
The current price is ₹112.07.
What is the 52-week price range?
The range is ₹85.46-169.
What is the market capitalization of the company?
The market capitalization is ₹2,877.76 crores.
What is the dividend yield?
The dividend yield is 2.14%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 9.14.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Alembic Limited (ISIN: INE426A01027) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹2,877.76 crores and an average daily volume of 652,952 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹2.4.